hIL-2 NOG小鼠, hIL-2 NOG Mice - 维通利华

产品服务 > 实验动物模型 > 查找动物模型品系

hIL-2 NOG Mice

品系代码：

412

专业名称：

NOD.Cg-Prkdc^scidIl2rg^tm1SugTg(CMV-IL2)4-2Jic/JicCrl

小鼠,免疫缺陷模型免疫学,肿瘤学同类系

【CIEM正式授权】表达人源细胞因子IL-2

品系来源

应用特性

价格规格

应用文献

品系来源

hIL-2 NOG小鼠由日本中央实验动物研究所（CIEM）培育而成。CIEM Mamoru Ito实验室通过将CMV启动子控制的含有hIL-2 cDNA的DNA转基因载体显微注射到NOD/ShiJic-Il2rg小鼠的受精卵中，构建出Founder品系。该Founder再与NOG小鼠回交，建立了稳定的hIL-2 NOG小鼠。

✈ 2020年，维通利华从CIEM引入该品系。

☑ 拓展阅读：hIL-2 NOG小鼠与T细胞治疗实体瘤临床前模型

应用特性

研究用途：

可能是IL-2依赖性细胞系/肿瘤（包括一些血癌）移植（CDX/PDX）的优化模型。
是基于NK细胞功能的ADCC（antibody-dependent cellular-cytotoxicity）研究的体内研究模型。
可用来评估CAR-T细胞疗法实体瘤的杀伤活性。
可用于癌症、传染病、免疫学、再生医学、人体免疫系统移植等研究。

特性：

毛色：白化

除了NOG小鼠的特性外，还具备以下特性：

表达人源细胞因子IL-2。
huHSC-CD34+移植hIL-2 NOG小鼠后人源NK细胞分化明显，CD56+NK细胞的数量是基础NOG小鼠的10倍以上。
huHSC-CD34+移植hIL-2 NOG小鼠后产生的人源NK细胞，能够表达各种NK细胞受体，刺激后也能够产生颗粒酶A和穿孔素。

价格规格

品系代码	品系名称	日/周龄	性别	VAF/SPF级	Elite/SPF级
412	hIL-2 NOG	1-8周	雌		1260

*以上规格与价格自2025年1月1日至2025年12月31日有效。

应用文献

hIL-2 NOG Publications

Authors	Year	Paper Title	Keywords
Matteo Morotti, et al.	2024	PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function	TIL, IL-2, CD8+ cytotoxic T lymphocyte
Stecklum, Maria, et al.	2024	Humanization of NOG mice and next generation NOG mouse strains	NOG, next-generation NOG, HSC, check point inhibitors
Colin Thalhofer, et al.	2024	Tumor reactive CD8 TIL with an exhausted phenotype can be expanded and regress human tumors	DP or DN TIL, PD-1, PDX
Anaïs Jiménez-Reinoso, et al.	2024	CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts	Adoptive cell therapy; bispecific T cell-engagers; cytotoxic CD4+ TIL; solid tumors; tumor-infiltrating lymphocytes
Khoshtinat Nikkhoi S, et al.	2024	Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice	HER2, CD16a, BiKE:E5C1, ADCC, laNK92, NK
Elin M. V. Forsberg, et al.	2023	Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs	CAR-TILs, HER2, PDX
Julien Schmidt, et al.	2023	Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.	adoptive cell therapy (ACT), TIL, Neoantigen
Christensen, Pernille Kristine Fisker et al.	2023	Sustaining the T-cell activity in xenografted psoriasis skin	psoriasis, autoimmune disease
MacLean S. Hall, et al.	2022	Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma	TILs, Nivolumab, combined therapy, metastatic melanoma
Liang, Frank et al.	2022	A Fraction of CD8+ T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells	MEK inhibition, colorectal liver metastases, tissue-resident memory T cells, tumor-infiltrating lymphocytes.
Kudling, Tatiana V et al.	2022	Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	oncolytic virus, adenovirus, immunotherapy, interleukin 7
Arvind Natarajan, et al.	2022	Preclinical activity and manufacturing feasibility of genetically modified PDCD-1 knockout (KO) tumor-infiltrating lymphocyte (TIL) cell therapy	TILS
Arnaud, M., Chiffelle, J., Genolet, R. et al.	2021	Sensitive identification of neoantigens and cognate TCRs in human solid tumors	ACT, TCRs
Özcan Çınar, et al.	2021	High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.	ACT, TCRs
Somsundar V Muralidharan, et al.	2020	Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells	ACT, melanoma
T. Helleday	2020	Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles	ACT, melanoma
L.Ny, et al.	2020	Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models	immunotherapy, melanoma, PDX
Elin M. V. Forsberg, et al.	2019	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice	melanoma,HER2, CAR-T, ACT,
Berglind O. Einarsdottir, et al.	2018	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma	melanoma, TILs,ACT
Paul Volden, et al.	2018	Cytokine-transgenic NOG mice engrafted with human peripheral blood cells support natural killer cell expansion	NK cell, ADCC, GvHD
Henrik Jespersen, et al.	2017	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.	melanoma, IL-2, tumor-infiltrating T lymphocytes (TILs), adoptive T-cell transfer (ACT),humanized,PDX
R.Ito, et al.	2016	A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4+ or CD8+ T Cells Using Immunodeficient NOG Mice	GvHD, CD8+ T cell,CD4+ T cell.
Ikumi Katano, et al.	2015	Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse	HSCs, humanized, NK cell,, ADCC